North Growth Management’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.5M Buy
63,000
+1,000
+2% +$353K 3.16% 11
2026
Q2
$22.4M Hold
62,000
– – 2.88% 8
2026
Q1
$15.6M Buy
62,000
+23,000
+59% +$5.72M 2.38% 12
2025
Q4
$10.8M Buy
39,000
+5,000
+15% +$1.37M 1.69% 23
2025
Q3
$8.93M Buy
34,000
+5,000
+17% +$1.22M 1.56% 30
2025
Q2
$6.36M Buy
29,000
+4,000
+16% +$855K 1.19% 32
2025
Q1
$5.49M Buy
25,000
+7,000
+39% +$1.93M 1.16% 35
2024
Q4
$5.96M Sell
18,000
-1,000
-5% -$315K 1.13% 36
2024
Q3
$5.56M Buy
19,000
+3,000
+19% +$919K 1.04% 38
2024
Q2
$5.16M Hold
16,000
– – 1.02% 39
2024
Q1
$6.19M Buy
16,000
+4,000
+33% +$1.48M 1.18% 40
2023
Q4
$4.34M Buy
12,000
+2,000
+20% +$708K 0.93% 41
2023
Q3
$3.61M Hold
10,000
– – 0.8% 41
2023
Q2
$3.75M Hold
10,000
– – 0.77% 41
2023
Q1
$3.4M Buy
+10,000
New +$2.92M 0.72% 41

Other funds holding WST

North Growth Management's WST Position: Q3 2026 in Review

North Growth Management increased its West Pharmaceutical (WST) stake by 1.6% in Q3 2026, buying an estimated $353K and bringing the position to 63,000 shares worth $23.5M. The position accounts for 3.16% of the portfolio, ranked #11.

North Growth Management first reported a position in WST in Q1 2023 and has held it in 15 quarters since. 881 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • North Growth Management held 63,000 shares of West Pharmaceutical worth $23.5M as of Q3 2026.
  • North Growth Management bought 1,000 West Pharmaceutical shares in Q3 2026, an estimated $353K.
  • West Pharmaceutical made up 3.16% of North Growth Management's portfolio in Q3 2026, its #11 holding.
  • North Growth Management first reported a position in West Pharmaceutical in Q1 2023 and has held it in 15 quarters since.
  • 881 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on North Growth Management's 13F filing for Q3 2026, filed 20 Oct 2026.